secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001570562-23-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus raises FY2023 revenue guidance to $185-195M, Q2 revenue $49.3M (+33% YoY)
--------------------------------------------------------------------------------

- Q2 net revenue $49.3M, up 33% YoY, a new quarterly record.
- FY2023 revenue guidance raised to $185-195M from prior $180-190M.
- Record ~800 new accounts, 64k new patient enrollments, 147k+ redemptions.
- Expanding into fillers in 2025; targeting $700M revenue by 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000082/0001570562-23-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000082/eols-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001570562-23-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer